On January 14, 2025 AimedBio reported it has entered into an exclusive global license agreement with U.S.-based Biohaven for the development and commercialization of AMB302, an FGFR3-targeting ADC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

– Under the agreement, Biohaven will lead the Phase 1 clinical trial in the United States.

– Financial details, including upfront payments and the total deal size, were not disclosed.

(Press release, AimedBio, JAN 14, 2025, View Source;s_keyword=&s_where=&start=10 [SID1234656918])